Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vivos Therapeutics

4.11
-0.5000-10.85%
Post-market: 4.120.0100+0.24%19:53 EDT
Volume:339.37K
Turnover:1.37M
Market Cap:24.21M
PE:-2.41
High:4.35
Open:4.33
Low:3.72
Close:4.61
52wk High:7.95
52wk Low:1.98
Shares:5.89M
Float Shares:3.82M
Volume Ratio:3.49
T/O Rate:8.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7047
EPS(LYR):-2.2184
ROE:-450.47%
ROA:-61.21%
PB:5.49
PE(LYR):-1.85

Loading ...

Vivos Therapeutics : Anticipates Material Increase in Net Loss for Three Months Ended June 30, 2025 as Compared to Three Months Ended June 30, 2024

THOMSON REUTERS
·
Yesterday

Vivos Therapeutics Inc. Delays Q2 2025 Financial Report Due to Recent Acquisition

Reuters
·
Yesterday

Vivos Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview

Reuters
·
Aug 08

Vivos Therapeutics Adds to Management Team to Support Expansion and Growth

GlobeNewswire
·
Jul 30

Vivos Therapeutics Shares Rise After Medicare Approval for VidaSleep

Dow Jones
·
Jul 02

BRIEF-Vivos Therapeutics Inc - Vidasleep Oral Appliance Approved By CMS Pdac

Reuters
·
Jul 01

Vivos announces results published of OSA using Daytime-Nighttime Appliance

TIPRANKS
·
Jun 26

Vivos Therapeutics Inc. Files Initial Beneficial Ownership Statement for Michael C. Skaff

Reuters
·
Jun 21

Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada, Secures Over $11 Million in New Financing

Reuters
·
Jun 14

Vivos Therapeutics completes acquisition of SCN for $6M in cash, $1.5M in stock

TIPRANKS
·
Jun 11

Vivos Therapeutics Inc. Appoints Baker Tilly as New Auditor Following Merger with Moss Adams

Reuters
·
Jun 07

Equity Markets Close Lower as Trump Proposes New Tariffs on EU, Apple

MT Newswires Live
·
May 24

Sector Update: Health Care Stocks Decline Late Afternoon

MT Newswires Live
·
May 24

Vivos Issues $1.1 Million Convertible Promissory Note

MT Newswires Live
·
May 24

Vivos Therapeutics Inc. Enters $1.1M Convertible Promissory Note with V-Co Investors for SCN Acquisition

Reuters
·
May 23

Vivos Therapeutics’ Earnings Call: Strategic Shifts Amid Financial Challenges

TIPRANKS
·
May 17

Vivos Therapeutics Reports Q1 2025: Product Revenue Up 8%, Gross Profit and Margin Decline Due to Shift in Business Model

Reuters
·
May 16

Vivos Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

BRIEF-Vivos Therapeutics Q1 Net Income USD -3.864 Million

Reuters
·
May 16

Vivos Therapeutics Q1 EPS $(0.45) Misses $(0.40) Estimate, Sales $3.02M Miss $3.67M Estimate

Benzinga
·
May 16